Effect of gemcitabine plus cisplatin in advanced breast cancer with anthracycines and /or taxanes resistance
- VernacularTitle:吉西他滨联合顺铂治疗蒽环类和(或)紫杉类耐药晚期乳腺癌的近期疗效观察
- Author:
Weidong WEI
;
Likun CHEN
- Publication Type:Journal Article
- Keywords:
breast neoplasmas;
gemcitabine;
cisplatin;
anthracycines;
taxanes
- From:China Oncology
2006;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Ever since the use of anthracycine and /or taxanes-based regimen for the adjuvant and/or neoadjuvnat chemotherapy of breast cancer,there have few sensitive agents for advanced breast cancer(ABC)when it occurs drug resistance to anthracycine and /or taxanes.The aim of this study is to evaluate the effect of gemcitabine plus cicplatin in advanced breast cancer after the failure of treatment with anthracycines and /or taxanes.Methods:From May,2005 to Jan 2007,34 ABC cases with anthracycine and/or taxanes resistance were treated with GEM(1000 mg/m2.day1,day8)and DDP(30 mg/m2,day 1 to day 3)every 3 weeks.A median of 5 cycles(2-6 cycles)of the treatment was delivered.All cases were followed up more than 6 months.Results:3 cases(8.8%)had complete response(CR),13 cases(38.2%)had partial response(PR),while 12 cases(35.3%)had stable disease(SD)and progressive disease(PD)was 6 cases(17.7%);the overall response rate was 47.0%.The median time to progression(TTP)was 6.5 months,grade 3/4 diarrhoea and thrombocytopenia were main side effects.Conclusions:GEM plus DDP are effective in the treatment of advanced breast cancer with anthracycine and/or taxanes resistance.
